MOULDER LEON O JR 4
4 · Zenas BioPharma, Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Zenas BioPharma (ZBIO) CEO Leon Moulder Buys 57,000 Shares
What Happened
Leon O. Moulder Jr., the chief executive officer and chairman of Zenas BioPharma (ZBIO), purchased 57,000 shares in open-market transactions on February 2, 2026. The filing reports a weighted average price of $17.96 per share for a total reported cost of $1,023,720. This was a purchase (insider buy), which many investors view as a potentially bullish signal, though it is not proof of future performance.
Key Details
- Transaction date: 2026-02-02 (Period of Report); Form 4 filed 2026-02-03 (timely filing).
- Price: weighted average $17.96; purchase prices ranged from $17.69 to $18.14 across multiple trades. The reporting person will provide a breakdown of quantities at each price upon request (Footnote F1).
- Shares acquired: 57,000 (open-market purchases). Total reported value: $1,023,720.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnotes of note:
- F1: Weighted-average price; multiple executions within $17.69–$18.14.
- F2–F3: Mr. Moulder is a trustee of a revocable trust and Managing Member of Tellus BioVentures LLC; he may be deemed to have voting/dispositive power over shares held by those entities but disclaims beneficial ownership except to the extent of any pecuniary interest.
Context
This was an open-market purchase (not an option exercise, award, or gift). Insider purchases are routinely monitored by retail investors as one data point about executive confidence, but they should be considered alongside other information about the company's fundamentals and strategy.
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-02-02$17.96/sh+57,000$1,023,720→ 423,155 total
- 36,928(indirect: See Footnote)
Common Stock
[F2] - 1,672,039(indirect: See Footnote)
Common Stock
[F3]
Footnotes (3)
- [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.69 to $18.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The reporting person is a Trustee of the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 (the "Trust") and may be deemed to have voting and dispositive power over the shares held by the Trust. The reporting person is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F3]Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.